26296954Issa JJ, Roboz G, Rizzieri D, Jabbour E, Stock W, O'Connell C, Yee K, Tibes R, Griffiths EA, Walsh K, Daver N, Chung W, Naim S, Taverna P, Oganesian A, Hao Y, Lowder JN, Azab M, Kantarjian HThe Lancet. OncologyAzacitidine; Dose-Response Relationship, Drug; Leukemia, Myeloid, Acute; Myelodysplastic SyndromesAdult; Aged; Antineoplastic Combined Chemotherapy Protocols; Decitabine; Disease-Free Survival; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; PrognosisSafety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015 Sep; 16(9):1099-1110.Lancet Oncol2015-08-19T00:00:002015Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.prns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD000368Living Beings1341183530.294764AgedD000328Living Beings1578255770.254432AdultD000971Procedures30624340.476235Antineoplastic Combined Chemotherapy ProtocolsD001374Chemicals & Drugs551370.924989AzacitidineD004305Concepts & Ideas52019580.724084Dose-Response Relationship, DrugD008875Concepts & IdeasLiving Beings1473249570.258811Middle AgedD009190Disorders543450.762111Myelodysplastic SyndromesD009367Concepts & IdeasProcedures34719320.670065Neoplasm StagingD005260Physiology1992444050.191167FemaleD006801Living Beings2262862810.130052HumansD008297Physiology1931408600.201617MaleMedicine-Hematology and OncologyD015470Disorders1227550.629242Leukemia, Myeloid, AcuteD011379Procedures74536690.561447PrognosisD018572Concepts & Ideas25812030.792696Disease-Free SurvivalD020714Concepts & Ideas902700.919873Maximum Tolerated DoseUniversity of ChicagoWendyStockwHF9BKIeOfnamXNnYUHhvWD+6g==Wendy Stock41.78927490000000-87.601250000000001502Stock, WendyProfessortrue1ProfessorProfessorAuthorship 8271450.1376640.1376641authors10.2515has subject area